Sage Journals: Discover world-class research

Retricted access

Research article

First published 2017-1

Understanding Human Over-reliance on Technology;It's Exelan,Not Exelon;Crash Cart Drug Mix-up;Risk with Entering a “Test Order”

Michael R. Cohen, Judy L. Smetzer

Hospital Pharmacy

Free access

Research article

First published 2017-9

Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers

Dhiraj Abhyankar, Ashish Shedage, Milind Gole [...]

American Journal of Alzheimer's Disease & Other Dementias®

Retricted access

Research article

First published 2022-09-13

Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System

Kun Bu, Devashru Patel, Robert Morris [...]

Journal of Alzheimer’s Disease

Free access

Review article

First published 2011-9

Rivastigmine in Alzheimer’s Disease and Parkinson’s Disease Dementia

Daniel Weintraub, Monique Somogyi, Xiangyi Meng

American Journal of Alzheimer's Disease & Other Dementias®

Retricted access

Research article

First published 2008-9

Into the New Millennium and Out of the Ordinary the Development of Millennium Park

Rachel Brewer

Collections: A Journal for Museum and Archives Professionals

Free access

Review article

First published 2018-3

Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease

Vinod Kaushik, Sarah Toombs Smith, Emmanuel Mikobi [...]

American Journal of Alzheimer's Disease & Other Dementias®

Free access

Research article

First published 2013-9

Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease

George Grossberg, Jeffrey Cummings, Lutz Frölich [...]

American Journal of Alzheimer's Disease & Other Dementias®

Search results

Understanding Human Over-reliance on Technology;It's Exelan,Not Exelon;Crash Cart Drug Mix-up;Risk with Entering a “Test Order”

Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers

Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System

Rivastigmine in Alzheimer’s Disease and Parkinson’s Disease Dementia

Into the New Millennium and Out of the Ordinary the Development of Millennium Park

Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease

Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease